Zavegepant

Zavegepant
Clinical data
Trade namesZavzpret
Other namesBHV-3500
License data
Routes of
administration		Nasal
Drug classCalcitonin gene-related peptide receptor antagonist
ATC code
Legal status
Legal status
Identifiers
  • N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC36H46N8O3
Molar mass638.817 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
  • InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
  • Key:JJVAPHYEOZSKJZ-JGCGQSQUSA-N
  • Key:VQDUWCSSPSOSNA-RYWNGCACSA-N

Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine. Zavegepant is a calcitonin gene-related peptide receptor antagonist. It is sprayed into the nose. It is sold by Pfizer.

The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting.

Zavegepant was approved for medical use in the United States in March 2023.

Medical uses

Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.

References

  1. 1 2 3 4 5 6 7 8 "Zavzpret- zavegepant spray". DailyMed. 9 March 2023. Retrieved 25 August 2023.
  2. ↑ "Drug Approval Package: Zavzpret". U.S. Food and Drug Administration (FDA). 3 April 2023. Archived from the original on 25 August 2023. Retrieved 25 August 2023.
  3. ↑ "Pfizer's Zavzpret (Zavegepant) Migraine Nasal Spray Receives FDA Approval" (Press release). 10 March 2023.
  4. ↑ Dhillon S (June 2023). "Zavegepant: First Approval". Drugs. 83 (9): 825–831. doi:10.1007/s40265-023-01885-6. PMC 10209931. PMID 37227596.
  5. ↑ Khan ZZ, Ahmed U, Shahzad F, Ali M, Tousif K, Ahmed U, et al. (July 2023). "Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review". Cureus. 15 (7) e41991. doi:10.7759/cureus.41991. PMC 10428082. PMID 37593294.
  6. ↑ Martirosov AL, Giuliano C, Shupp M, Channey S, Kale-Pradhan PB (October 2023). "Zavegepant Intranasal Spray for Migraines". The Annals of Pharmacotherapy. 58 (8): 827–833. doi:10.1177/10600280231209439. PMID 37897226. S2CID 264543368.

Further reading